AHA In Brief
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific TAXUS I: Angiographic analysis at six-month follow-up of 61 patients demonstrated zero edge effect at the proximal and distal edges in both the treatment and control arm of the paclitaxel-coated Nirx stent trial. Intravascular ultrasound (IVUS) analysis showed "significant improvements" in neointimal volume, percent neointimal volume index and minimum lumen area in the treatment group, the firm says. The newly reported data "expand on the impressive results reported earlier, and they reduce the concern that an edge effect may be the price we pay for reducing in-stent restenosis," commented Eberhard Grube, MD, Seigburg Heart Center, Siegburg, Germany...
You may also be interested in...
Transcathether Cardiovascular Therapeutics Meeting In Brief
Carotid stenting: MedNova EmboShield wire-filter distal protection system used with Xact self-expanding carotid stents is associated with a 7.2% 30-day major adverse event rate, according to preliminary results from the SECuRITY registry. Presented at the recent Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. by investigator Patrick Whitlow, MD, Cleveland Clinic, the data included evaluation of the devices in 305 patients with high surgical risks. The trial is being supported by Abbott Vascular, which has exclusive distribution rights (1"The Gray Sheet" Feb. 5, 2001, p. 23)...
Alsius, Radiant, InnerCool Heat Up Hypothermia Market Competition
Alsius Corp. expects to be the first to market with an intravascular temperature management system for controlling fever in the neuro-critical care setting, pending FDA clearance of a December 2001 510(k) submission
Alsius, Radiant, InnerCool Heat Up Hypothermia Market Competition
Alsius Corp. expects to be the first to market with an intravascular temperature management system for controlling fever in the neuro-critical care setting, pending FDA clearance of a December 2001 510(k) submission